Concordance between Patients and Clinicians for Reporting Symptoms Associated with Treatment for Chronic Hepatitis C during a Pragmatic Clinical Trial
Table 1
Sample characteristics of 1058 adults with chronic HCV.
Characteristic
Statistic
Age
Years-mean (SD)
54.9 (11.8)
Sex— (%)
Female
430 (40.6%)
Male
628 (59.4%)
Race— (%)
White
538 (50.9%)
Black
454 (42.9%)
Other
45 (4.2%)
Ethnicity— (%)
Hispanic
59 (5.6%)
Non-Hispanic
971 (91.8%)
Health insurance— (%)
Medicaid
419 (39.6%)
Medicare
196 (18.5%)
Private
375 (35.4%)
Uninsured
51 (4.8%)
Other
17 (1.6%)
Body mass index
Mean (SD)
28.5 (6.3)
Obese category (≥30)— (%)
386 (36.5%)
Medical comorbidities
Mean (SD)
3.5 (1.7)
1-2 comorbidities— (%)
368 (34.8%)
3-4 comorbidities— (%)
411 (38.8%)
5+ comorbidities— (%)
279 (26.4%)
Cirrhosis— (%)
No
881 (83.3%)
Yes
177 (16.7%)
Psychiatric comorbidities— (%)
None
686 (64.8%)
1+ comorbidities
372 (35.2%)
DAA treatment regimen— (%)
EBR/GZR
612 (57.8%)
LDV/SOF
316 (29.9%)
PrOD
130 (12.3%)
Ribavirin use— (%)
No
910 (86.0%)
Yes
148 (14.0%)
Virologic outcome— (%) of those with virologic outcome
Sustained virologic response
875 (96.2%)
Virologic failure
35 (3.8%)
Note: some percentages may not add to 100% as there was missing. Abbreviations: SD: standard deviation; DAA: direct acting antiviral; EBR/GZR: elbasvir/grazoprevir (Zepatier™); LDV/SOF: ledipasvir/sofosbuvir (Harvoni®); PrOD: paritaprevir/ritonavir/ombitasvir + dasabuvir (Viekira Pak/Viekira XR™).
